MesotheliomaPhase 1NCT06885697
TNhYP218 CAR T Cells
Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma
Trabedersen (OT-101) With Pembrolizumab for Newly Diagnosed Advanced NSCLC and Positive PD-L1
What the film says
Lung cancer is America's leading cancer killer. When tumors carry the marker PD-L1, treatment now starts with pembrolizumab, which takes the brakes off the immune system. It helps some; most tumors find a way through.
One way is a molecule called TGF-beta two, which tumors pour out to tell immune cells to stand down.
The idea: cut off that molecule while pembrolizumab does its work.
Trabedersen is a short strand of synthetic DNA that binds the instructions for TGF-beta two so they cannot be read. It has been tried before, in pancreatic cancer and glioma.
This trial, at the University of Nebraska with Omar Abughanimeh, gives it by infusion with pembrolizumab, and asks first what dose is safe. Public record; not medical advice.
Sources behind this film
Leading cancer killer in the US
Reck M. N Engl J Med, 2016
PD-L1-positive NSCLC starts with pembrolizumab; helps some, most progress
Mok TSK. Lancet, 2019
PD-L1-positive NSCLC starts with pembrolizumab; helps some, most progress
PD-L1-positive NSCLC starts with pembrolizumab; helps some, most progress; TGF-β2 suppresses immune cells and helps tumors evade; Trabedersen: synthetic antisense oligodeoxynucleotide against TGF-β2 mRNA; Given before in pancreatic cancer and glioma (+2 more lines)
Schlingensiepen KH. Cancer Sci, 2011
Trabedersen: synthetic antisense oligodeoxynucleotide against TGF-β2 mRNA
Oettle H. Journal of Clinical Oncology, 2012
Given before in pancreatic cancer and glioma
Bogdahn U. Neuro Oncol, 2011
Given before in pancreatic cancer and glioma
The drug
Trabedersen (OT-101) is a synthetic antisense oligodeoxynucleotide that specifically inhibits the production of Transforming growth factor-beta 2 (TGF-β2).
Pembrolizumab is a humanized anti-programmed death (PD-1) monoclonal antibody.
The main question(s) it aims to answer are: * What medical problems to participants have when taking OT101 together with Pembrolizumab? * What is the correct dose of OT-101 to use when evaluating the safety and efficacy of the combination therapy? * Does the combination therapy delay progression or relapse of the participants Non-Small Cell Lung Cancer? Participants will: * Receive intravenous OT-101/Trabedersen for 4 days once every 2 weeks.
The study
The goal of this clinical trial is to: 1) evaluate the safety and recommended dose of the drug OT-101/Trabedersen when combined with Pembrolizumab and 2) determine the efficacy of the combination therapy in adults with certain types of Non-Small Cell Lung Cancer.
The main question(s) it aims to answer are: * What medical problems to participants have when taking OT101 together with Pembrolizumab? * What is the correct dose of OT-101 to use when evaluating the safety and efficacy of the combination therapy? * Does the combination therapy delay progression or relapse of the participant's Non-Small Cell Lung Cancer? Participants will: * Receive intravenous OT-101/Trabedersen for 4 days once every 2 weeks.
Eligibility
Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.
For you, or someone you love
A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.
Then $9 a month. Cancel anytime.
Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.
Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.
Ask about your own file, and walk in with questions for your oncologist or the trial team.
Share one profile with the family helping you, and with your doctors.
Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.